International Journal of Clinical Pharmacy

, Volume 35, Issue 4, pp 532–534

Eosinophilia associated with bupropion

  • Montserrat García
  • Borja Ruiz
  • Carmelo Aguirre
  • Esther Etxegarai
  • Unax Lertxundi
Case Report

Abstract

Case (description)

A 48-year-old woman started treatment with bupropion 150 mg once daily for depressive symptoms. After 19 days she presented to her family physician complaining of myalgia and non-productive cough. The physical examination was normal and laboratory investigations showed an eosinophil count of 4.7 × 109/L (0–0.5). The results of a basal test before to bupropion intake were within normal range including eosinophils (0.2 × 109/L). After ruling out other causes of eosinophilia, the physician decided to gradually discontinue bupropion, and a marked decrease in absolute eosinophil count was subsequently observed.

Conclusion

To the best of our knowledge, this is the third published case of bupropion-related eosinophilia. Although, in light of the case presented, the prevalence of this adverse effect seems to be low, an awareness that bupropion can be a potential cause of eosinophilia may lead to the avoidance of unnecessary diagnostic tests or referral to other specialists.

Keywords

Antidepressants Bupropion Depression Eosinophilia 

References

  1. 1.
    Product Information: WELLBUTRIN® (bupropion). Research Triangle Park, NC: GlaxoSmithKline. http://www.pdr.net/drugpages/productlabeling.aspx?mpcode=32704625 (2011). Accessed 19 Dec 2012.
  2. 2.
    Bupropion. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex. Accessed 19 Dec 2012.Google Scholar
  3. 3.
    Malesker MA, Soori GS, Malone PM, Mahowald JA, Housel GJ. Eosinophilia associated with bupropion. Ann Pharmacother. 1995;29:867–9.PubMedGoogle Scholar
  4. 4.
    Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol. 2003;90:572–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Weller PF. Approach to the patient with eosinophilia. In: Mahoney DH, Bochner BS, editors. UpToDate. UpToDate: Waltham, MA; 2012.Google Scholar
  6. 6.
    Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol. 2009. doi:10.1155/2009/495863.
  7. 7.
    Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Australian Database of Adverse Event Notifications. www.tga.gov.au/daen/daen-entry.aspx. Accessed 19 Dec 2012.
  9. 9.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149–59.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Montserrat García
    • 1
  • Borja Ruiz
    • 1
    • 2
  • Carmelo Aguirre
    • 1
    • 2
  • Esther Etxegarai
    • 3
  • Unax Lertxundi
    • 4
  1. 1.Basque Country Pharmacovigilance UnitHospital Galdakao-UsansoloGaldakaoSpain
  2. 2.Department of Pharmacology, Faculty of MedicineUniversity of Basque CountryLeioaSpain
  3. 3.Txurdinaga Health CenterBilbaoSpain
  4. 4.Pharmacy ServiceAraba′s Mental Health NetworkVitoria-GasteizSpain

Personalised recommendations